November 27, 2007 08:43 AM Eastern Time
Pluristem's Proprietary PLX Cells Demonstrate Promising Potential in
Treating Autoimmune Disorders
NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics, Inc. (OTCBB:PSTI)
(DAX:PJT), a leading bio-therapeutics Company dedicated to the
commercialization of non-personalized (allogeneic) cell therapy
products for a variety of malignant, ischemic and autoimmune
disorders, announced today that in vitro testing of its PLacenta
eXpanded (PLX) cells demonstrated the potential to treat autoimmune
disorders. This testing showed a significant reduction of TNF-á and
interferon-ã inflammatory cytokines that are known to be involved in
the pathogenesis of autoimmune disorders. Reducing TNF-á and
interferon-ã is considered a key factor in mitigating the symptoms of
autoimmune disorders, such as Multiple Sclerosis (MS), Rheumatoid
Arthritis (RA), Crohn's Disease and Juvenile (Type 1) Diabetes.
"We are excited that our PLX cells demonstrate the potential to treat
autoimmune disorders," said Zami Aberman, Pluristem's President and
CEO. "The strong anti-inflammatory results show that our PLX cells
may have the capability to help millions of patients and represent an
additional potential multi-billion dollar market for our PLX cells.
These impressive results suggest that our 3D-expanded placental cells
could become an allogeneic, non-controversial source for stem cell
therapeutics in the future."
About Pluristem
Pluristem Therapeutics, Inc. is a Company dedicated to the
commercialization of non-personalized (allogeneic) stem cell therapy
products for the treatment of numerous severe degenerative, malignant
and autoimmune disorders. The Company's first product, PLX-I, is
directed at resolving the global shortfall of matched tissue for bone
marrow transplantation (BMT) by improving the engraftment of
hematopoietic stem cells (HSCs) contained in umbilical cord blood
(UCB).
Pluristem's products are derived from mesenchymal stromal cells
(MSCs) obtained from the placenta and not from embryonic stem cells.
They are expanded in the Company's proprietary PluriXTM 3D bioreactor
that imitates the natural microstructure of bone marrow and does not
require supplemental growth factors, cytokines or other exogenous
materials. Pluristem believes the resultant expanded cells, termed
PLX cells, are multi-potent and able to differentiate into a variety
of cell types as well as being immune-privileged to protect the
recipient from immunological reactions that often accompany
transplantation.
Pluristem has offices in the USA with research and manufacturing
facilities in Israel. For more information, please visit our website
at www.pluristem.
release.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and federal securities laws. These
forward-looking statements are based on the current expectations of
the management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
For example, when we speak about the strong anti-inflammatory results
showing that our PLX cells may have the capability to help millions
of patients and represent an additional potential multi-billion
dollar market for our PLX cells, we are using forward-looking
statements. The following factors, among others, could cause actual
results to differ materially from those described in the forward-
looking statements: changes in technology and market requirements;
our technology may not be validated as we progress further and our
methods may not be accepted by the scientific community; we may be
unable to retain or attract key employees whose knowledge is
essential to the development of our products; unforeseen scientific
difficulties may develop with our process; results in the laboratory
may not translate to equally good results in real surgical settings;
our patents may not be sufficient; our products may harm recipients;
changes in legislation; inability to timely develop and introduce new
technologies, products and applications; loss of market share and
pressure on pricing resulting from competition, which could cause the
actual results or performance of Pluristem to differ materially from
those contemplated in such forward-looking statements. Except as
otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements to
reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events. For a more detailed
description of the risk and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with
the Securities and Exchange Commission.
Contacts
Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.
or
CEOcast
Michael Wachs, 212-732-4300
mwachs@ceocast.
http://www.business
ndmViewId=news_
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
